http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
TheraVet : BIOCERA-VET® is Now Available for the Management of Dental and Orthopedics Conditions in Horses
-
BIOCERA-VET® Is Now Available for the Management of Dental and Orthopedics Conditions in Horses
-
TheraVet Retains a Leading US Veterinary Consulting Firm to Help Strategize Company Growth on the US Market
-
TheraVet Strengthens Its Intellectual Property With the Issuance of a Patent on VISCO-VET Technology in Europe, Israël & Singapore
-
TheraVet Reports an 99% Increase in BIOCERA-VET® Units Sold in Q4 2023
-
TheraVet: Commercial Launch of BIOCERA-VET® in Germany
-
TheraVet: Agreement with Alcyon Italia for the Distribution of BIOCERA-VET® Product Line in Italy
-
TheraVet Reports Significant Success of Its Last Educational Webinar on Canine Osteosarcoma Co-Organized With Veterinary Instrumentation
-
TheraVet Reports Further Achievements on Its Osteosarcoma Program
-
TheraVet: Launch of BIOCERA-VET® Canine Osteosarcoma Study Conducted by the Prestigious University of Florida
-
TheraVet Announces the Setting up of an Equity-Linked Financing Facility and Updates on Its Financing Strategy
-
TheraVet: Significant Sales Progression for BIOCERA-VET® in Q3 2023
-
TheraVet Announces the Appointment of a Chief Financial Officer to Reinforce Its Global Financing and Cost Control Strategy
-
TheraVet: Increasingly Successful Attendance in Major Ortho EU & US Conferences and North America Launch of BIOCERA-VET COMBO-CLEAN
-
TheraVet: BIOCERA-VET in Horse Bone Cysts Highlighted at an International Equine Conference in the USA
-
TheraVet: Patient Recruitment Phase Successfully Completed in BIOCERA-VET Fracture Revision Surgery Study in Toy Dogs
-
TheraVet Reports Its 2023 Half-year Results and Provides an Update on the Development of Its Activities
-
TheraVet provides an update on its 2023 half-year development and portfolio strategy
-
TheraVet Announces 300% Increase in Participating Centers in the Osteosarcoma Program Since Its Initiation 6 Months Ago
-
TheraVet Announces the Commercial Launch of a Local and Sustained Antibiotic Releasing Bone Substitute
-
TheraVet Continues the Assessment of BIOCERA-VET in a New Clinical Program
-
TheraVet reports Full-Year 2022 Financial Results and provides the preparatory documents for the General Assembly of June 1st, 2023
-
TheraVet Launches its Osteosarcoma Reference Centers Program
-
TheraVet Updates on Its Development and Portfolio Strategy
-
TheraVet Signs an International Distribution Agreement for BIOCERA-VET® Covering 24 Countries
-
TheraVet Announces the Start of the Assessment of BIOCERA-VET® in Horse Bone Cyst
-
TheraVet Optimizes Its Commercial Strategy in France With a New Distribution Agreement for Its BIOCERA-VET® Range
-
TheraVet: BIOCERA-VET® Nominated for the Veterinary Innovation Award (AFVAC 2022)
-
TheraVet Announces an Exclusive Distribution Agreement for BIOCERA-VET® in the USA
-
TheraVet Announces Its Participation in the 2022 ESVOT Congress With 3 Scientific Communications
-
TheraVet Reports Its 2022 Half-year Results and Provides an Update on the Development of Its Activities
-
TheraVet Provides Its 2022 First Half-year Operational Update
-
TheraVet Annonces the Commercial Launch of its BIOCERA-VET Product Line in the United States of America
-
TheraVet Annonces the Commercial Launch of the Most Comprehensive Line of Bone Substitutes in the Veterinary Market
-
TheraVet Signs a Distribution Agreement With Nuzoa, a Leading Spanish Company in the Distribution of Veterinary Products and Services
-
TheraVet: General Meeting of June 2, 2022: Availability of Preparatory Documents
-
TheraVet Signs an Important Distribution Agreement With the Orthopaedics & Surgical Instrumentation Distributor, Veterinary Instrumentation
-
TheraVet Reports Full Year 2021 Financial Results and Confirms Its Ambitious Development and Commercial Plans for 2022
-
TheraVet: Market-making Agreement with Banque Rothschild
-
TheraVet: Commercial Launch of BIOCERA-VET® in United Kingdom and Ireland
-
TheraVet Broadens Its Bone Substitutes Portfolio With an Innovative Line of Biological Bone Grafts
-
TheraVet: Positive Results of BIOCERA-VET®-Bone Surgery Presented at the Annual Conference of the US Veterinary Orthopedic Society and Confirmed on a Larger Patients Cohort
-
TheraVet Provides Its 2021 Second Half Operational Update
-
TheraVet Strengthens Its Sales Organisation in France by Signing an Important Distribution Agreement for BIOCERA-VET®
-
TheraVet Announces the Initiation of Coverage of Its Stock by Degroof Petercam
-
TheraVet Is Strengthening Its Corporate Governance With the Appointment of Three New Independent Board Members
-
TheraVet: Commercial Launch of BIOCERA-VET® for Canine Osteosarcoma in Belgium, France and The Netherlands
-
TheraVet Broadens Significantly its BIOCERA-VET® Product Line Through Major Distribution and Research Agreements
-
TheraVet Announces Positive Safety and Efficacy Results for BIOCERA-VET® in Canine Osteosarcoma
-
TheraVet: Commercial launch of BIOCERA-VET® in France and The Netherlands
